Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and ...

Oral semaglutide reduced major cardiovascular ... according to late-breaking results from the phase 3 SOUL trial. 1 These findings were presented Saturday, March 29, at the American College ...

Trial confirms that oral semaglutide lowers cardiovascular risk in type 2 diabetes, regardless of SGLT2i use. Read more!

Preventive cardiologist Neha Pagidipati, MD (Duke University School of Medicine, Durham, NC), called SOUL an important clinical trial because it confirms the cardiovascular benefits of oral ...

Once-daily orforglipron was more effective than placebo and just as safe as injectable GLP-1s in patients with diabetes and ...

Both the injectable and oral forms of semaglutide ... such as heart attacks and stroke. The Semaglutide cardiOvascular oUtcomes triaL (SOUL) recruited 9,650 people for the study who had pre ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the risk of major adverse ...

Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its positions in peripheral artery disease (PAD) and with an oral formulation, based ...

Both the injectable and oral forms of semaglutide ... such as heart attacks and stroke. The Semaglutide cardiOvascular oUtcomes triaL (SOUL) recruited 9,650 people for the study who have pre ...